(S)-N-(1-carbamoyl-2-hydroxy-ethyl)-3-fluoro-4-(3-fluoro-benzyloxy)-benzamide | 636792-25-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-N-(1-carbamoyl-2-hydroxy-ethyl)-3-fluoro-4-(3-fluoro-benzyloxy)-benzamide
• 英文别名: N-[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]-3-fluoro-4-[(3-fluorophenyl)methoxy]benzamide
• CAS: 636792-25-1
• 化学式: C₁₇H₁₆F₂N₂O₄
• 分子量: 350.322
• InChiKey: LBEIGJOUIVMQLQ-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  102
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-fluoro-4-(3-fluoro-benzyloxy)-benzoic acid 生成 (S)-N-(1-carbamoyl-2-hydroxy-ethyl)-3-fluoro-4-(3-fluoro-benzyloxy)-benzamide 、 H-Ser-NH2HCl
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Fluorobenzamides and uses thereof
  申请人：——

  公开号：US20030236304A1

  公开（公告）日：2003-12-25

  The invention relates to fluorobenzamide derivatives of the formula 1 wherein R 1 , R 2 , R 3 R 4 , R 5 , R 6 and R 7 are as defined herein. =, The compounds of the invention are selective monoamine oxidase B inhibitors and therefore they are suitable for the treatment of diseases mediated by monoamine oxidase B, such as Alzheimer's disease or senile dementia.

  这项发明涉及公式1的氟苯甲酰胺衍生物，其中R1、R2、R3、R4、R5、R6和R7如本文所定义。该发明的化合物是选择性单胺氧化酶B抑制剂，因此它们适用于治疗由单胺氧化酶B介导的疾病，如阿尔茨海默病或老年痴呆症。
• FLUOROBENZAMIDES SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SENILE DEMENTIA
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1515926A2

  公开（公告）日：2005-03-23
• MAO-B INHIBITORS USEFUL FOR TREATING OBESITY
  申请人：McElroy Francis John

  公开号：US20070078172A1

  公开（公告）日：2007-04-05

  The invention provides a method of treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance) in a mammal by administering to the mammal a therapeutically effective amount of an irreversible MAO-B inhibitor.
• US6951884B2
  申请人：——

  公开号：US6951884B2

  公开（公告）日：2005-10-04
• [EN] FLUOROBENZAMIDES<br/>[FR] FLUOROBENZAMIDES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2003106380A2

  公开（公告）日：2003-12-24

  The present invention is concerned with fluorobenzamide derivatives of the general formula Wherein R1 is hydrogen, (C1-C6)-alkyl or hydroxy-(C1-C6)-alkyl; R2 is (C1-C6)-alkyl, -CO-NR8R9, -(CH2)n-NR8R9, -(CH2)P-OR8, or -(CH2)n-CN; R3 is selected from hydrogen, halogen, halogen-(C1-C6)-alkyl, cyano, C1 -C6-alkoxy or halogen-(C1-C6)-alkoxy; R4, R5, R6 and R7 are hydrogen or fluoro, and at least one of R4, R5, R6 and R7 is fluoro; R8 and R9 independently from each other are hydrogen or (C1-C6)-alkyl; m is 1, 2 or 3; n is 0, 1, 2 or 3; and p is 1 or 2; as well as their pharmaceutically acceptable salts. The compounds of general formula I are selective monoamine oxidase B inhibitors and therefore they are suitable for the treatment of Alzheimer's disease or senile dementia.